What is the appropriate dosage of hydroxyurea for hyponatremia?

Hydroxyurea is NOT indicated for the treatment of hyponatremia

Hydroxyurea does not treat hyponatremia—it can actually CAUSE severe hyponatremia as a rare but serious adverse effect. If you are asking about dosing hydroxyurea in a patient who has hyponatremia, you must first discontinue the hydroxyurea if it is the causative agent 1.

Critical Clinical Context

There appears to be a fundamental misunderstanding in this question. Let me clarify the relationship between hydroxyurea and hyponatremia:

Hydroxyurea as a CAUSE of Hyponatremia

Hydroxyurea can induce sodium-losing nephropathy leading to severe, symptomatic hyponatremia. A documented case report describes a 79-year-old patient on hydroxyurea 1500 mg/day who developed severe hyponatremia (serum sodium 119 mEq/L) with consciousness disturbance and high urinary sodium excretion. Upon discontinuation of hydroxyurea, urinary sodium excretion decreased and consciousness cleared as serum sodium normalized 1.

Appropriate Hydroxyurea Dosing (For Its Actual Indications)

Hydroxyurea is indicated for myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, primary myelofibrosis) and sickle cell disease—NOT for electrolyte disorders.

Standard dosing for myeloproliferative neoplasms:

• Initial therapeutic dose: At least 2 g/day (approximately 20-30 mg/kg/day) for 3 months to assess response 2, 3
• Dose escalation to maximum tolerated dose may be considered based on response and toxicity
• Treatment failure is defined when adequate response is not achieved after 3 months at ≥2 g/day

Clinical Algorithm If Hyponatremia Develops on Hydroxyurea

1. Immediately suspect hydroxyurea as the causative agent if patient presents with hyponatremia and high urinary sodium excretion
2. Discontinue hydroxyurea
3. Treat the hyponatremia according to standard protocols:
   • For severe symptomatic hyponatremia: 100-150 ml boluses of 3% sodium chloride 4
   • Monitor sodium correction closely to avoid overcorrection
   • Recent evidence suggests rapid correction (≥8-10 mEq/L per 24 hours) is associated with lower mortality than very slow correction 5
4. Monitor for improvement in urinary sodium excretion and serum sodium levels
5. Consider alternative therapy for the underlying hematologic condition (e.g., ruxolitinib for polycythemia vera, interferon, or other agents)

Key Pitfall to Avoid

Do not continue hydroxyurea in a patient with drug-induced hyponatremia. The sodium-losing nephropathy will persist as long as the drug is continued, and the hyponatremia will not resolve with standard treatments while the causative agent remains 1.